Celldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum
Investors view quarterly updates from clinical-stage biotechs in a much different way from how they view those of other companies. When Celldex Therapeutics (NASDAQ: CLDX) reported its first-quarter results earlier this year, the focus wasn't on its revenue but instead on the company's cash position and clinical update.
Celldex announced its second-quarter results after the market closed on Tuesday, and the biotech's financial performance still wasn't the main attraction. Celldex's bigger news related to what's going on with its pipeline. Here are the highlights from the company's update.
Image source: Getty Images.
Source: Fool.com
Merck & Co. Inc. Aktie
104,60 €
-0,19 %
Die Community bevorzugt klar Merck & Co. Inc. mit vielen Buy- und nur wenigen Sell-Einschätzungen.
Das Kursziel von 125 € für Merck & Co. Inc. weist auf eine leichte Verbesserung gegenüber dem aktuellen Kurs von 104.6 € hin.
